Exposure to Antibodies Anti-Chlamyphila Pneumoniae Associated to Respiratory Symptoms of Asthma among Adolescents.

Authors
Guadalupe García-Elorriaga1*
Maximino Miranda-García2
Guillermo Del Rey-Pineda3
Luisa María Sánchez-Zamorano4
Eduardo César Lazcano-Ponce5
Eduardo Salazar-Martínez6

1* Medical Research Unit in Immunology and Infectology. Hospital of Infectology. National Medical Center “La Raza”, Mexican Institute of Social Security, Mexico City, Mexico.
E mail: gelorriaga@webtelmex.net.mx

Email: maximino.miranda@imss.gob.mx

3 Blood Central Bank, Medical Center “La Raza”, Mexican Institute of Social Security, Mexico City, Mexico Infectology Department. Children Hospital of Mexico “Federico Gómez”. Minister of Health, Mexico City, Mexico
E mail: gdelrey@prodigy.net.mx

4 Center of Research in Population Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
E mail: szamoran@insp.mx

5 Academic Secretariat, School of Public Health of Mexico, Cuernavaca, Morelos, Mexico.
E mail: elazcano@insp.mx

6 Chronical Diseases Division, Center of Research in Population Health, National Institute of Public Health.. Cuernavaca, Morelos, Mexico.
Email: esalazar@insp.mx

*Corresponding author.
National Medical Center La Raza, CMNR. Mexican Social Security Institute, IMSS, Av. Jacarandas y Seris, Col. La Raza, PC: 02990. Ciudad de México, México.
Phone: +52(55) 5724 5900; Fax: +52(55) 5353 0989;
Email: gelorriaga@webtelmex.net.mx.

Conflict of interests: The authors declare that they have no conflict of interest.

The submission has not been previously published, nor presented before another journal for consideration.
Abstract
Previous report shows relationship between *C. pneumoniae* and Asthma. In this study, we assessed the association between exposure to *C. pneumoniae* infection and the risk of bronchial asthma in adolescents in the State of Morelos, Mexico. An analysis was performed on a population-based cohort study of 80 adolescents with respiratory symptoms of asthma defined by ISAAC and 202 healthy adolescents between 12 and 17 years old. The information was collected twice from questionnaires, anthropometry, and sampling. Excessive weight gain was determined by calculating body mass index, and exposure to the specific antibodies IgM, IgG, and IgA was detected by microimmunofluorescence. The geometric means were calculated for titers of *C. pneumoniae*. The odds ratio was used across multiple models. The results showed that the exposure to *C. pneumoniae* was very high in the study population (67.2%). All immunoglobulins were significantly increased in patients with asthma symptoms compared with the healthy population (17% for IgG, 34% for IgM, and 52% for IgA). In multiple models, the IgM and IgA immunoglobulins were found to be associated with asthma (OR, 2.4; 95% CI, 1.4–4.2 and OR, 2.4; 95% CI, 1.2–4.8, respectively). Our study reflects a high seroprevalence of *C. pneumoniae* in the population; this seroprevalence is higher in young people with asthma. Specific immunoglobulins to *C. pneumoniae* are associated with IgM and IgA. The epidemiological significance of our results influences the timely monitoring and management of infections acquired at an early age that persist, or recur, for much of the juvenile life. Additional studies are needed to validate our findings.

**Keywords:** Asthma; *Chlamydia pneumoniae*; risk factors; immunoglobulins; microimmunofluorescence.
1. Introduction
Asthma is a chronic inflammatory disease that is related to hyper-reactivity of the airways and characterized by repeated episodes of wheezing and dyspnea. This disease represents the most frequent chronic respiratory disease among adolescents in different countries, with prevalence ranging from 2.1% to 32.2% in children 12 to 14 years old. For example, Brazil has reported a prevalence of between 12.4 to 25.2% in adolescents 13–14 years old, while the estimated prevalence in Mexico City is 9.9% in the same age group and approximately 5% in all adolescents. In other locations in Mexico, the prevalence are similar, including 12% in Merida and Yucatan and 7.3% in Tamaulipas. Epidemiological and clinical studies have suggested that there is a causal relationship between recurrent infections of the upper respiratory tract and the development of airway hyper-reactivity and respiratory allergies in children during subsequent subclinical or asymptomatic infection.

Chlamydia pneumoniae (C. pneumoniae) has been reported since the early 1990’s to have a significant etiopathogenic role in the development of acute, atypical infections of the respiratory tract. C. pneumoniae infection is potentially associated with the onset of wheezing and asthma and with a greater exacerbation of the symptomatology of respiratory diseases, including pneumonia, chronic obstructive pulmonary disease, and chronic asthma. There is evidence that a wide variety of microorganisms are present in the lower airway and may play a role in asthma pathogenesis, suggests that manipulating the airway microbiome may be a novel approach towards this goal. Studies confirm the existence of an infectious etiology mediated by C. pneumoniae. Among the various infections associated with asthma, this obligate intracellular respiratory pathogen C. pneumoniae is of particular interest, as it is associated with both asthma severity and treatment resistance. Likewise, evidence links C. pneumoniae infection with both de novo asthma (asthma onset during/after an acute lower respiratory tract infection in a previously non-asthmatic individual, also referred to as the “infectious asthma” syndrome). Has been shown by serology to be one of the most prevalent infectious agents worldwide. Recently, the seroprevalence of the infection in asthmatics and the frequency of associated exacerbations has varied as a function of either the populations studied or the geographic area; for example, positive serology for C. pneumoniae of up to 48.1% has been reported in children and adolescents in Peru.

Fetal exposure to tobacco smoke has been given special consideration. It has been demonstrated that the newborns of mothers who smoke have poorer respiratory function and a higher prevalence of respiratory disease or wheezing. Another factor reported for the deterioration of pulmonary function is obesity. Mexico has one of the leading places in the world, both in adulthood (with a prevalence of 71%) as well as in childhood and adolescence (28% in males and 30% in females).
With this background, we proposed to evaluate the possible association between exposure to *C. pneumoniae* and the risk of asthma in adolescents in Mexico.

### 2. Materials and methods

#### 2.1 Study population

The information was obtained from a cohort study, which recruited 13,293 students of both genders, aged between 11 to 17 years old, from the public education system of the State of Morelos in 1998–2001. The participants were selected during the baseline measurements by random sampling stratified by geographical area of the state and by clusters of the lists that integrated the public schools of the State of Morelos. The project was accepted by the State Institute of Public Education and approved by the Ethics Committee of the National Institute of Public Health. The participants signed letters of agreement, and consent was given by the parents. In our analysis, a total of 282 adolescents were selected from the original list of the cohort, which consisted of the complete information from the questionnaires and blood samples.

#### 2.2 Variable results

We used the standard definition of asthma proposed by the International Study of Asthma and Allergies in Childhood (ISAAC). Briefly, the asthma variable was established under the following conditions: If the diagnosis of asthma or asthmatic bronchitis was established by a treating physician, or if the adolescent had a dry cough and/or repetitive wheezing nightly or after the performance of exercise in the last 12 months.

#### 2.3 Definition of exposure

Serologic tests were performed in a blinded fashion using the microimmunofluorescence (MIF) test developed by Wang and Grayston. *C. pneumoniae* elementary bodies were used as antigens in the MIF test, and the IgG, IgM, and IgA were detected. *C. trachomatis* and *C. psittaci* antigens were included in the test. Cross-reactions between the different chlamydial species and the immunological activity of the LPS in the *C. pneumoniae* and *C. trachomatis* antigens appear to be low. In the literature, IgA has been considered to be a marker of chronic *C. trachomatis* infections.

#### 2.4 Test Principle: This test was based on the indirect detection of the IgG, IgM, and IgA antibodies against *C. pneumoniae* using fluorescein isothiocyanate (FITC) as the marker compound. The antibodies for *C. pneumoniae* in the patient’s serum were combined with *C. pneumoniae* antigens fixed on the surface of a glass slide. The slide was washed, followed by the addition of fluorescein conjugated with anti-human antibodies. The slides were then revealed and detected with an epifluorescence microscope. An acute infection was defined in a patient as an elevated IgG titer 4 times higher relative to standard sera; if two paired sera were

---

unavailable, an IgM titer of 16 or a single IgG titer of 512 with a compatible clinical history were usually considered sufficient. A past infection was defined as IgG titers of 16 but 512, whereas a recurrent infection was defined as IgA titers of 16.

The MIF method, with a high negative predictive value (98%) and a high sensitivity for the detection of chlamydial infections, was used.

Table 1. Baseline characteristics of population (n=282). Mexico, 2012

<table>
<thead>
<tr>
<th>Factor</th>
<th>Asthmatics (n=80)</th>
<th>Non asthmatics (N=202)</th>
<th>“P”value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, SD)</td>
<td>14.6 (2.6)</td>
<td>14.1 (1.8)</td>
<td>0.03&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Immunoglobulin G (&lt;em&gt;mean&lt;/em&gt;, &lt;em&gt;SD&lt;/em&gt;)</td>
<td>19.6 (15.1)</td>
<td>12.9 (6.8)</td>
<td>&lt;0.01&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Immunoglobulin M (&lt;em&gt;mean&lt;/em&gt;, &lt;em&gt;SD&lt;/em&gt;)</td>
<td>12.2 (7.1)</td>
<td>11.7 (3.4)</td>
<td>0.44&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Immunoglobulin A (&lt;em&gt;mean&lt;/em&gt;, &lt;em&gt;SD&lt;/em&gt;)</td>
<td>12.6 (3.5)</td>
<td>10.5 (4.9)</td>
<td>&lt;0.01&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Moderate physical activity, METs/h/w (&lt;em&gt;mean&lt;/em&gt;, &lt;em&gt;SD&lt;/em&gt;)</td>
<td>3.8 (0.6)</td>
<td>3.9 (0.5)</td>
<td>0.60&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Vigorous physical activity, METs/h/w (&lt;em&gt;mean&lt;/em&gt;, &lt;em&gt;SD&lt;/em&gt;)</td>
<td>14.8 (7.1)</td>
<td>15.1 (6.5)</td>
<td>0.70&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>52 (65)</td>
<td>118 (58.4)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>28 (35)</td>
<td>84 (41.6)</td>
<td>0.30&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Body mass index&lt;sup&gt;c&lt;/sup&gt;, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight</td>
<td>7 (8.7)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>54 (67.6)</td>
<td>103 (51.0)</td>
<td></td>
</tr>
<tr>
<td>Overweight</td>
<td>12 (15.0)</td>
<td>68 (33.6)</td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td>7 (8.7)</td>
<td>31 (15.3)</td>
<td>&lt;0.01&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Smoking, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>65 (81.2)</td>
<td>151 (74.7)</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>9 (11.2)</td>
<td>36 (17.8)</td>
<td></td>
</tr>
<tr>
<td>Ever</td>
<td>6 (9.5)</td>
<td>15 (7.4)</td>
<td>0.42&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
2.5 Co-variables
The body composition information was obtained via standard measurement procedures. Briefly, a Tanita digital scale with a precision of 0.01 mm of error was used to measure weight; a stadiometer was used to measure height. The students were measured and weighed barefoot and with minimal clothing. The body mass index (BMI) was calculated according to the formula: weight (kg) / height (m²). Physical activity was measured continuously in Metabolic Equivalent for Task (MET) units through a questionnaire of daily physical activity previously validated for the Mexican population. Moderate physical activity was identified based on a cut-off point of 3 to 5 METs/hour/week; vigorous physical activity was defined by a cutoff point of > 5 METs/hour/week. The smoking variable was evaluated in 3 categories according to each students’ status as a non-smoker, ex-smoker, and current smoker.

2.6 Statistical analysis
The results of the descriptive analysis are presented as percentages, means, and standard deviations. Student’s t-tests were used to compare two samples of continuous variables, whereas 2-tailed ANOVA tests were used for three samples. For this analysis, we used the inverse of the dilution results of the MIF reading (converted into the base 2 logarithmic scale) and reported the resultant geometric means. Finally, a multiple logistic regression model was used, and the 95% confidence intervals were calculated to determine statistical significance.

3. Results
In the baseline evaluation, the asthmatic participants were slightly older than the controls (p = 0.03); twice as many control subjects were overweight or obese compared to the asthma patients (p < 0.01). Variables such as sex, smoking, and physical activity showed no differences between the two groups. The asthmatic participants showed higher IgG and IgA concentrations compared with the controls (p < 0.01) (Table 1).

When comparing the concentrations of the immunoglobulins during the follow-up, we found a negative absolute difference in IgM and IgA but not in IgG, in the asthmatic participants. The controls showed negative absolute differences in the concentrations of IgM and IgA that were similar to the cases, whereas IgG showed a positive absolute difference. The frequency of exposure during the period was 55% for IgG in the asthmatic participants, whereas in the controls, it was 45.5%. The exposure to IgM in the cases was 50.6% compared to the controls, which showed only 33.6%. The frequency of exposure for IgA decreased, but in the asthmatic participants, it was double when compared with the controls (23.1 vs. 11.1%, respectively) (Table 2). This result indicated that the asthmatic participants showed increases in the exposure of IgG, IgM, and IgA of 17%, 34%, and 52%, respectively. The overall prevalence of all the immunoglobulins during the study period was 67.2% (77.5% for the cases and 59.4% for the controls).
Table 2. Comparison of Immunoglobulin levels between groups in baseline and follow-up (n=282), Mexico 2012

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Follow-up</th>
<th>Absolute Difference</th>
<th>Average of exposure in Period, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Immunoglobulins, Gmᵃ (SD)</td>
<td>Immunoglobulins, Gmᵃ (SD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IgG</td>
<td>IgM</td>
<td>IgA</td>
</tr>
<tr>
<td>Asthmatics</td>
<td>80</td>
<td>19.6 (15.1)</td>
<td>12.2 (7.1)</td>
<td>12.6 (3.5)</td>
</tr>
<tr>
<td>Non asthmatics</td>
<td>20</td>
<td>12.9 (6.3)</td>
<td>11.7 (3.4)</td>
<td>10.5 (4.9)</td>
</tr>
</tbody>
</table>

ᵃ Geometric mean

In the multiple regression models, IgG showed no association (OR, 1.1; 95% CI, 0.6–1.9), whereas IgM (OR, 2.4; 95% CI, 1.4–4.2) and IgA (OR, 2.4; 95% CI, 1.2–4.8) were correlated with an increased risk of asthma (Table 3). We stratified by BMI, physical activity and tobacco use founded an association between IgM (OR, 2.38; 95% CI, 1.21–4.67) and IgA (OR, 2.77; 95% CI, 1.10–7.00) to obesity and normal weight respectively, meanwhile IgM was associated to moderate physical activity. On the other hand never smokers were associated to IgM (OR, 2.05; 95% CI, 1.05–4.00) and to IgA (OR, 2.57; 95% CI, 1.16–5.70) (Table 4).

Table 3. Distribution of asthma cases and non-asthmatics by immunoglobulin levels with Odds ratios and confidence intervals, México, 2012.

<table>
<thead>
<tr>
<th>Immunoglobulins</th>
<th>Asthmatics</th>
<th>Non asthmatics</th>
<th>ORᵃ</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunoglobulin G</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>36</td>
<td>97</td>
<td>1.0ᵇ</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>44</td>
<td>105</td>
<td>1.1</td>
<td>0.6 – 1.9</td>
</tr>
<tr>
<td>Immunoglobulin M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>41</td>
<td>146</td>
<td>1.0ᵇ</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>39</td>
<td>56</td>
<td>2.4</td>
<td>1.4 – 4.2</td>
</tr>
<tr>
<td>Immunoglobulin A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>61</td>
<td>179</td>
<td>1.0ᵇ</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>19</td>
<td>23</td>
<td>2.4</td>
<td>1.2 – 4.8</td>
</tr>
</tbody>
</table>

ᵃ Adjusted for Body mass index (CDC tables), Smoking (not/former/yes) and physical activity (continuous), age and sex.
ᵇ Reference category

Copyright 2021 KEI Journals. All Rights Reserved  http://journals.ke-i.org/index.php/mra
Table 4. Odds ratio and confident intervals of asthma cases by immunoglobulin levels stratified for BMI, physical activity and tobacco use. Mexico, 2012.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Immunoglobulin G (+)(^a)</th>
<th>Immunoglobulin M (+)(^a)</th>
<th>Immunoglobulin A (+)(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR(^b) 95% CI</td>
<td>OR(^b) 95% CI</td>
<td>OR(^b) 95% CI</td>
</tr>
<tr>
<td><strong>Body Mass Index</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(weight/height(^2))</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>1.21 0.63 - 2.32</td>
<td>2.38 1.21 - 4.67</td>
<td>2.77 1.10 - 7.00</td>
</tr>
<tr>
<td>Overweight/obesity</td>
<td>0.84 0.30 - 2.37</td>
<td>3.34 1.08 - 10.3</td>
<td>2.66 0.81 - 8.72</td>
</tr>
<tr>
<td><strong>Physical activity (Mets/h/d)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>0.83 0.17 - 4.10</td>
<td>1.23 0.22 - 6.70</td>
<td>2.36 0.36 - 15.1</td>
</tr>
<tr>
<td>Moderate</td>
<td>0.26 0.05 - 1.26</td>
<td>10.8 2.04 - 57.4</td>
<td>1.14 0.86 - 15.2</td>
</tr>
<tr>
<td>Vigorous</td>
<td>1.54 0.79 - 3.02</td>
<td>1.84 0.92 - 3.70</td>
<td>3.53 1.50 - 8.37</td>
</tr>
<tr>
<td><strong>Smoking</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>1.10 0.58 - 2.06</td>
<td>2.05 1.05 - 4.00</td>
<td>2.57 1.16 - 5.70</td>
</tr>
<tr>
<td>Former</td>
<td>2.13 0.24 - 22.2</td>
<td>40.7 1.74 - 94.6</td>
<td>2.13 0.08 - 51.6</td>
</tr>
<tr>
<td>Current</td>
<td>1.05 0.24 - 4.40</td>
<td>3.23 0.77 - 13.5</td>
<td>3.80 0.41 - 35.1</td>
</tr>
</tbody>
</table>

\(^a\) Reference category is immunoglobulin (-) in each strata
\(^b\) Odds ratio adjusted all variables used in table 3

4. Discussion

4.1 Seroprevalence

The selected population showed a *C. pneumoniae* infection rate of 67.2% according to microimmunofluorescence. However, the external validity of our study is limited to adolescents in the State of Morelos.

The prevalence of infection was notably higher in the asthmatic cases compared with the healthy population. When evaluating the exposure according to the type of immunoglobulin, it was found that IgG was the most prevalent, followed by IgM and IgA. Notably, the largest difference in exposure to *C. pneumoniae* was correlated with IgA in the asthmatic cases when compared with the healthy controls. These results are comparable with the findings of other international groups, which have reported different prevalences of anti-*C. Pneumoniae* detected by MIF. For example, in Middle Eastern countries such as Israel\(^{29}\), seroprevalences of 31% and 74% have been found in children and in adults, respectively, with no seasonal preferences; by contrast, in Jordan\(^{30}\), the overall seropositivity was 54%, which increased with increasing age, and only 14.7% of cases of infection, as indicated by IgM, were recently acquired. On the other hand, in Iran\(^{31}\), 11.6% and 65.5% seroprevalences for IgG in children and adults, respectively, have been detected by ELISA. In Singapore\(^{32}\), the seroprevalence for *C. pneumoniae* (IgG) determined by MIF reached up to 70%; the
seroprevalence was the lowest in the younger age group (18–29 years), 48% for both sexes, and ascended with age up to 78.9%. That study population included Chinese, Malays, and Asian Indians, who showed no differences when compared.

4.2 Associated immunoglobulins
In our study, multiple models showed a significant 2-fold association with IgM and IgA (OR, 2.4) in subjects with asthma, whereas IgG showed no association (95% CI, 0.6–1.9). Previous reports have shown diversity in relation to these immunoglobulins. Thus, a case-control study conducted with 196 children and young individuals showed no association with either IgG (p = 0.12) or IgA (p = 0.18) detected via MIF. 33 However, in a cross-sectional study of 369 young adults, C. pneumoniae infection measured by means of IgG and IgM (MIF) showed an association with respiratory symptoms of cough and phlegm in asthmatic subjects (OR, 1.80; 95% CI: 1.01–3.36 and OR 2.31; 95% CI: 1.20–4.42, respectively). 34 Another study was conducted on 3 groups of subjects: 141 asthmatic participants, 62 allergic participants without asthma, and 125 healthy controls were evaluated, and a higher prevalence for IgA (OR, 5.9; 95% CI, 1.7–26.2) and IgA+IgG (OR, 5.2; 95% CI, 1.6–25.8) were found in the allergic and asthmatic subjects compared to the non-asthmatics. 35 On the other hand, in a study aimed at determining whether the prevalence changes with seasonality, 127 asthmatic participants were recruited and were compared with 391 controls from young adults. The authors found a decrease in the seroprevalence of IgG in both groups at 6 months of observation. This number was reduced in the summer by more than 20% in both groups, but increased in the winter by 10% in the asthmatic participants and by 5% in the non-asthmatic participants. 36 We also performed a cohort analysis using absolute values and a period seroprevalence, which showed an increase of all the immunoglobulins, with IgA being the most prominent and presenting with average values that were doubled in the asthmatic participants. However, seasonality was not assessed in the study periods.
Several reports have been showed obesity related to increased risk of asthma among children and teenagers using clinical criteria, for instance a cohort study 37 among 2,171 children and adolescents in USA founded a positive association (HR,1.51; 95% CI, 1.08–2.10). In the same way in Greece 38, a case-control study performed among 514 adolescents reported an association between obesity and asthma (OR, 1.52, 95% CI 1.03–2.70). In the USA it was reported that the adjusted risk for incident asthma was increased among children who were overweight (relative risk [RR]: 1.17; 95% confidence interval (CI): 1.10–1.25) and obese (RR: 1.26; 95% CI: 1.18–1.34). 39 In China 40 a meta-analysis was done, a total of 13 studies were included, including 2 case–control studies, 6 cohort studies, and 5 cross-sectional studies. It was observed a positive association between abdominal obesity and asthma (OR = 1.47, 95% CI 1.35–1.59). Likewise, in China 41 was found in a meta-analysis, a bidirectional association between obesity and asthma.
during childhood and adolescence. There was a statistically significant association between obesity and increased risk of physician-diagnosed asthma in children and adolescents (RR was 1.39 (95% CI: 1.28, 1.50; p < 0.001). For the association of asthma with risk of childhood obesity, (RR was 1.47 (95%CI: 1.25, 1.72; p < 0.001). Another cohort study in USA showed direct association between persistent obesity and asthma diagnosed by clinical criteria and allergen specific IgE levels (RR, 2.4; 95% CI, 1.2-4.7). The National Health and Nutrition Examination Survey (NHANES) using data from 1999-2006 reported an association between obesity and asthma defined by clinical criteria, self-report and stratified by IgE (OR, 2.46, 95% CI, 1.21-5.02 for atopic children and OR, 1.34, 95% CI, 0.70-2.57 for non-atopic children). Our study showed consistency with these reports especially in IgM (OR, 3.34; 95% CI, 1.08-10.3).

Participation of physical activity as risk factor asthma has been reported for few authors, but most important issue is referent to increased physical activity to prevent asthma or asthma crisis. Our results showed and direct association to moderate physical activity, nevertheless prevalence in both (asthmatics and non-asthmatics) was similar and the sample size was small.

4.3 Limitations
Although some our results are consistent with different reports, we must note that our study was conducted with a reduced sample size despite being embedded in a cohort study. We considered the IgG titers to indicate chronic exposure and those of IgA to indicate re-infection; however, this should be taken with caution because, due to the immune response, we have not necessarily affirmed persistent infection. However, our cohort design and the high prevalence of C. pneumoniae enabled us to show that the infection is chronic and is consistent with the persistence of the symptoms in the participants. Another potential limitation is that we did not evaluate IgE, which has been reported by recent studies of C. pneumoniae infection in asthmatics be an important immunoglobulin, reaching a seroprevalence of up to 50% in these patients when compared to the healthy population. The proposed mechanism responsible for this difference is the capability of these immunoglobulins to induce an allergic response by producing T-helper 2 peripheral blood mononuclear cells (PBMC). On the other hand, there may be an association between C. pneumoniae, asthma and production of IgE responses in PBMC; IL-4 is required for IgE production.

5. Conclusions
Our study reflects a high seroprevalence of C. pneumoniae in the population that is higher in young people with symptoms of asthma. Similarly, IgM and IgA are the specific immunoglobulins associated with C. pneumoniae infection. The epidemiological significance of our results influences the timely monitoring and management of C. pneumoniae infection in populations exposed at an early age to this bacterium and in cases that persist or recur throughout much of the juvenile life.
More studies are needed to validate our findings and to evaluate bronchial reactivity to C. pneumoniae.

Acknowledgements
This work was carried out with funds granted by the Bristol-Mayers Squibb Foundation (New-York), under initiative called “Better Health for Women: A Global Health Program”. Likewise, National Council of Science and Technology of Mexico (CONACyT in Spanish) number: 34487-M.

Authorship
GGE was the principal investigator for laboratory work and assisted with data interpretation and manuscript writing; MMG, GRP, and LMSZ were responsible for the biochemical data collection and analysis, and provided critical review of the manuscript; ELP contributed to data interpretation and provided critical review of the manuscript; ESM was responsible for data analyses, data interpretation and primary manuscript writing. All authors have read and approved the final manuscript.

Ethical responsibilities
Protection of people
The authors declare that the procedures followed were in accordance with the ethical standards of the responsible human experimentation committee and in accordance with the World Medical Association and the Declaration of Helsinki.

Right to privacy and informed consent.
The participants signed letters of agreement, and consent was given by the parents.

Conflict of interests
The authors declare that they have no conflict of interest.
References


21. Miranda Candelario JF. Atypical microorganisms in children with...


